Topic: JPM 2019

Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.

Alexion aims to transform from an ultrarare-disease company to a rare-disease company—and to make that happen, its pricing has to change.

CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.

Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.

What's on Tuesday's talking points memo at JPM? Drug launches, hoped-for FDA nods, deals, rivalries, FDA tea leaves—and one unexpected tax bill.

There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to.

To make sense of Sanofi's Dengvaxia experiences, look no further than the old adage: Learn from your mistakes.

The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.

Pharma came storming out of the gate at this year's J.P. Morgan meeting in a Monday full of deal talk, CEO ambitions and analyst prognostications.

CEOs for BMS and Celgene took to the J.P. Morgan Healthcare Conference to explain the rationale for their $74 billion megadeal.